Escitalopram Treatment of Night Eating Syndrome

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Night-Eating Syndrome (NES) is an eating disorder characterised by excessive eating at night, sleep disturbance and morning anorexia. This 12-week study examines the effect of escitalopram on symptoms of NES.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brain Imaging and Treatment Studies of the Night Eating Syndrome

NCT01401595

Night Eating Syndrome

COMPLETED PHASE3

Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder

NCT00442481

Major Depressive Disorder

UNKNOWN PHASE4

Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder

NCT04013464

Depressive Disorder, Major

COMPLETED NA

Brain Network Dynamics of Depression During Esketamine Treatment

NCT06012916

Depressive Disorder, Major

COMPLETED

Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

NCT00220701

Dysthymic Disorder

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Night Eating Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Escitalopram

Group Type EXPERIMENTAL

Escitalopram

Intervention Type DRUG

10-20 mg

B

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

10-20 mg

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-70 years
* Presence of NES
* BMI 25-50

Exclusion Criteria

* History of schizophrenia or other psychoses
* History of bipolar disorder, anorexia nervosa, bulimia, binge eating disorder
* Current major depressive disorder
* Suicidal ideation
* Psychotropic drugs in the past month
* Drugs or herbal remedies that significantly affect body weight, current participation in a weight loss program, currently following a specialized diet (e.g., Atkins, Zone, etc)
* Lack of benefit with SSRI treatment for NES
* Serious or unstable medical illness
* Allergy or hypersensitivity to escitalopram
* Pregnant, breast-feeding, or planning pregnancy in the next six months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No